HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
DIS3L2
DIS3 like 3'-5' exoribonuclease 2
Chromosome 2 Β· 2q37.1
NCBI Gene: 129563Ensembl: ENSG00000144535.21HGNC: HGNC:28648UniProt: Q8IYB7
55PubMed Papers
21Diseases
0Drugs
99Pathogenic Variants
FUNCTIONAL ROLE
Tumor Suppressor
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
mitotic sister chromatid separationcytoplasmP-bodyRNA nuclease activityPerlman syndromealcohol drinkingAbnormality of the skeletal systemfacial morphology
✦AI Summary

DIS3L2 encodes a 3'-5' exoribonuclease that specifically recognizes and degrades polyuridylated RNAs in the cytoplasm 1. The enzyme contains RNA-binding domains (two CSD domains and one S1 domain) and an RNB catalytic domain responsible for exoribonuclease activity 1. DIS3L2 functions in cytoplasmic RNA surveillance by degrading uridylated substrates including pre-microRNAs, mature microRNAs, mRNAs, and other noncoding RNAs 12. The enzyme undergoes dramatic conformational changes triggered by double-stranded RNA, repositioning cold shock domains by 70 Γ… and exposing a trihelix linker that acts as a wedge to separate RNA strands 3. DIS3L2 plays crucial roles in preventing innate immune activation by degrading aberrant cellular RNAs that would otherwise trigger interferon responses 2. Loss of DIS3L2 function is associated with Perlman syndrome, an overgrowth disorder, and Wilms tumor predisposition 45. The enzyme controls cell proliferation through conserved pathways involving imaginal disc growth factors and PI3-Kinase/AKT signaling 4. Children with heterozygous germline DIS3L2 variants show increased rates of metastatic and high-risk blastemal Wilms tumors 5.

Sources cited
1
DIS3L2 is a 3'-5' exoribonuclease with specific domain structure that degrades polyuridylated RNAs
PMID: 30638126
2
DIS3L2 prevents innate immune activation by degrading aberrant RNAs
PMID: 41401009
3
DIS3L2 undergoes conformational changes to degrade structured RNAs
PMID: 36823385
4
DIS3L2 controls cell proliferation through conserved pathways
PMID: 33370287
5
Germline DIS3L2 variants predispose to Wilms tumor with high-risk features
PMID: 40481679
Disease Associationsβ“˜21
Perlman syndromeOpen Targets
0.82Strong
alcohol drinkingOpen Targets
0.45Moderate
Abnormality of the skeletal systemOpen Targets
0.44Moderate
facial morphologyOpen Targets
0.30Weak
ovarian dysfunctionOpen Targets
0.29Weak
NephroblastomaOpen Targets
0.26Weak
Benign Thyroid Gland NeoplasmOpen Targets
0.26Weak
male reproductive organ cancerOpen Targets
0.24Weak
transient ischemic attackOpen Targets
0.20Weak
genetic disorderOpen Targets
0.19Weak
liver diseaseOpen Targets
0.18Weak
Neurodevelopmental disorderOpen Targets
0.12Weak
osteoarthritisOpen Targets
0.12Weak
HepatoblastomaOpen Targets
0.11Weak
diabetic nephropathyOpen Targets
0.10Weak
HypermetropiaOpen Targets
0.09Suggestive
Abnormality of the genital systemOpen Targets
0.09Suggestive
dementiaOpen Targets
0.09Suggestive
colorectal carcinomaOpen Targets
0.08Suggestive
Benign Ovarian NeoplasmOpen Targets
0.07Suggestive
Perlman syndromeUniProt
Pathogenic Variants99
NM_152383.5(DIS3L2):c.645del (p.Cys216fs)Pathogenic
Perlman syndrome|DIS3L2-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 216
NM_152383.5(DIS3L2):c.2170C>T (p.Arg724Ter)Pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 724
NM_152383.5(DIS3L2):c.127C>T (p.Arg43Ter)Pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 43
NM_152383.5(DIS3L2):c.325dup (p.Asp109fs)Pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 109
NM_152383.5(DIS3L2):c.1096G>T (p.Glu366Ter)Pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 366
NM_152383.5(DIS3L2):c.733C>T (p.Arg245Ter)Pathogenic
Perlman syndrome|DIS3L2-related disorder
β˜…β˜…β˜†β˜†2024β†’ Residue 245
NM_152383.5(DIS3L2):c.1810C>T (p.Gln604Ter)Pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 604
NM_152383.5(DIS3L2):c.994G>T (p.Glu332Ter)Likely pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 332
NM_152383.5(DIS3L2):c.1162C>T (p.Arg388Ter)Pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 388
NM_152383.5(DIS3L2):c.1983del (p.Thr662fs)Pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 662
NM_152383.5(DIS3L2):c.1740-1G>CLikely pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2023
NM_152383.5(DIS3L2):c.2302del (p.Leu768fs)Pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2023β†’ Residue 768
NM_152383.5(DIS3L2):c.48del (p.Arg17fs)Pathogenic
Perlman syndrome
β˜…β˜…β˜†β˜†2021β†’ Residue 17
NM_152383.5(DIS3L2):c.209A>G (p.Gln70Arg)Pathogenic
Perlman syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 70
NM_152383.5(DIS3L2):c.2011-1G>CLikely pathogenic
Perlman syndrome
β˜…β˜†β˜†β˜†2024
NM_152383.5(DIS3L2):c.1545del (p.Ile516fs)Pathogenic
Perlman syndrome
β˜…β˜†β˜†β˜†2024β†’ Residue 516
NM_152383.5(DIS3L2):c.1420_1421del (p.Gly474fs)Pathogenic
Perlman syndrome
β˜…β˜†β˜†β˜†2024β†’ Residue 474
NM_152383.5(DIS3L2):c.2289+1G>ALikely pathogenic
Perlman syndrome
β˜…β˜†β˜†β˜†2024
NM_152383.5(DIS3L2):c.799_800del (p.Leu267fs)Pathogenic
Perlman syndrome
β˜…β˜†β˜†β˜†2024β†’ Residue 267
NM_152383.5(DIS3L2):c.367-2A>GPathogenic
Perlman syndrome
β˜…β˜†β˜†β˜†2024
View on ClinVar β†—
Related Genes
MTREXProtein interaction100%HBS1LProtein interaction99%EXOSC9Protein interaction97%EXOSC10Protein interaction97%SUPV3L1Protein interaction97%C1DProtein interaction97%
Tissue Expression6 tissues
Ovary
100%
Bone Marrow
90%
Lung
70%
Liver
62%
Heart
59%
Brain
47%
Gene Interaction Network
Click a node to explore
DIS3L2MTREXHBS1LEXOSC9EXOSC10SUPV3L1C1D
PROTEIN STRUCTURE
Preparing viewer…
PDB8E2A Β· 2.80 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.47Moderately Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.35 [0.26–0.47]
RankingsWhere DIS3L2 stands among ~20K protein-coding genes
  • #8,189of 20,598
    Most Researched55
  • #787of 5,498
    Most Pathogenic Variants99 Β· top quartile
  • #2,681of 17,882
    Most Constrained (LOEUF)0.47 Β· top quartile
Genes detectedDIS3L2
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
The roles of the exoribonucleases DIS3L2 and XRN1 in human disease.
PMID: 27911720
Biochem Soc Trans Β· 2016
1.00
2
Regulation of RNA decay and cellular function by 3'-5' exoribonuclease DIS3L2.
PMID: 30638126
RNA Biol Β· 2019
0.90
3
DIS3L2-mediated RNA surveillance and extracellular vesicle packaging prevent innate immune activation by aberrant cellular RNAs.
PMID: 41401009
Proc Natl Acad Sci U S A Β· 2025
0.80
4
RNA 3'end tailing safeguards cells against products of pervasive transcription termination.
PMID: 39617768
Nat Commun Β· 2024
0.70
5
N6-methyladenosine RNA modification regulates the transcription of SLC7A11 through KDM6B and GATA3 to modulate ferroptosis.
PMID: 39800682
J Biomed Sci Β· 2025
0.60